...
首页> 外文期刊>癌と化学療法 >Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX)
【24h】

Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX)

机译:顺铂(CDDP)和紫杉醇(PTX)的序贯联合应用基于TS-1的化疗有效治疗不可切除的晚期胃癌

获取原文
获取原文并翻译 | 示例
           

摘要

The patient was a 66-year-old female with Borrmann's type 4 gastric cancer complicated by metastasis to the liver and invasion of the head of the pancreas. Radical resection was not indicated, and only gastrojejunostomy was performed to bypass an existing pyloric obstruction. One course of chemotherapy was defined as 3 weeks of drug administration(TS-1 100 mg/body/day po for 21 days + CDDP 9 0 mg/body/day by iv drip on day 8), followed by a 2-week rest period. Chemotherapy was started 13 days after the operation, and it was possible to continue it for 7 courses. TS-1/CDDP therapy improved the patient's general condition. The tumor marker levels were also decreased. However, the efficacy of treatment began to decline,and ascites gradually developed during the fourth course of therapy. The treatment regimen was then switched to TS-1 100 mg/body/day po for 14 days, followed by a 14-day rest period, combined with PTX 9 0 mg/body/day iv drip on day 1 and day 15, while the ascites was being controlled. The ascites decreased significantly after the change in regimen, and the new regimen was continued for 6 courses. However, PTX was switched to CPT-11 because of gradual progression of peripheral neuropathy as a side effect of chemotherapy, and the patient subsequently died without any improvement in symptoms. This report describes a case of advanced gastric cancer treated by combination chemotherapy with TS-1 as a key drug, which resulted in a long survival (1 year and 5 months)and improvement in quality of life.
机译:该患者是一名66岁女性,患有Borrmann's 4型胃癌,并发转移至肝脏和胰头侵犯。未进行根治性切除术,仅进行胃空肠吻合术以绕过现有的幽门梗阻。化疗的一个疗程定义为给药3周(TS-1 100 mg /人/天,口服21天+ CDDP 9 0 mg /人/天,第8天静脉滴注),然后休息2周期。术后13天开始进行化学疗法,有可能继续进行7个疗程。 TS-1 / CDDP治疗改善了患者的总体状况。肿瘤标志物水平也降低。然而,在第四疗程中,治疗功效开始下降,并逐渐发展为腹水。然后将治疗方案改为TS-1 100 mg /人/天,口服14天,然后休息14天,在第1天和第15天静脉滴注PTX 9 0 mg /人/天,同时腹水得到控制。改变方案后,腹水明显减少,新方案继续进行6个疗程。然而,由于周围神经病变逐渐发展为化疗的副作用,PTX切换为CPT-11,患者随后死亡,症状无任何改善。该报告描述了一例以TS-1为关键药物的联合化疗治疗的晚期胃癌,其生存期较长(1年零5个月),生活质量得到改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号